Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years
Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years have?
Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years has 402 citations in the OpenAlex counts ScholarIQ stores.
When was Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years published?
Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years has 2009 year in the ScholarIQ index.
What is the open-access status of Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years?
Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years has bronze oa status in the ScholarIQ index.
What is the DOI of Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years?
The DOI for Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years is on the source record.
What is the PMID of Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years?
The PMID for Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years is on the source record.
What is the OpenAlex record for Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years?
The OpenAlex for Comparison of the immunogenicity and safety of<i>Cervarix</i>™ and<i>Gardasil</i><sup>®</sup>human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years is on the source record.